Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout

Soleno finished 2025 with $190.4 million in net revenue from sales of Vykat. Neurocrine expects Vykat’s numbers to improve in coming years, since the drug is positioned as a foundational first-line therapy for PWS and is supported by a patent portfolio that is expected to protect the drug’s exclusivity into the mid-2040s. The post Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout appeared first on GEN - Genetic Engineering and Biotechnology News.